{"id":"717a7250-910a-4642-8f0e-c5a477b4ecdc","slug":"extensive-spontaneous-cervical-epidural-hematoma-due-to-oral-anticoagulant-dabigatran-successfully-treated-with-reversal-agent-idarucizumab-alone","title":"Extensive spontaneous cervical epidural hematoma due to oral anticoagulant (dabigatran) successfully treated with reversal agent idarucizumab alone","authors":["Syed-Abdullah Uddin","Katerina Roma","Lindsey Ross","George Hanna","Doniel Drazin","Terrence T. Kim"],"abstract":"Background: Dabigatran is an anticoagulant (novel oral anticoagulant) that is a direct thrombin inhibitor and only recently has a reversal agent, idarucizumab, been made available (2015). Case Description: An 86-year-old male taking dabigatran for atrial fibrillation, acutely presented with the spontaneous onset of neck pain and quadriparesis. When the MRI demonstrated a C2-T2 spinal epidural hematoma, the patient was given the reversal agent idarucizumab. Due to his attendant major comorbidities, he was managed nonoperatively. Over the next 7 days, the patient’s neurological deficits resolved, and within 2 weeks, he had regained normal neurological function. Conclusion: In this case, a C2-T2 epidural cervical hematoma attributed to dabigatran that was responsible for an acute, spontaneous quadriparesis was successfully treated with the reversal agent idarucizumab without surgical intervention being warranted.","thumbnailUrl":"https://sni-digital-videos.s3.amazonaws.com/articles/717a7250-910a-4642-8f0e-c5a477b4ecdc/featured/hero-1781561249870.png","publishDate":"2022-06-23T00:00:00.000Z","doi":"10.25259/SNI_929_2021","categories":["Spine","Case Report"],"fullTextUrl":"https://surgicalneurologyint.com/api/articles/717a7250-910a-4642-8f0e-c5a477b4ecdc/pdf"}